Navigation Links
CSHL study identifies potential way to reverse cancer cell metabolism and tumor growth
Date:1/22/2010

Cold Spring Harbor, N.Y. A team of scientists led by Professor Adrian Krainer, Ph.D., of Cold Spring Harbor Laboratory has discovered molecular factors in cancer cells that boost the production of an enzyme that helps alter the cells' glucose metabolism. The altered metabolic state, called the Warburg effect, promotes extremely rapid cell proliferation and tumor growth. Adrian Krainer, Ph.D.

Discovered eighty years ago by Nobel Prize-winning scientist Otto Warburg, this altered metabolism in cancer cells is most critically mediated by a protein called PK-M2 (pyruvate kinase M2). This is one of two versions or isoforms of the enzyme pyruvate kinase, whose other isoform, PK-M1, is harmless.

In a study published online ahead of print in the Proceedings of the National Academy of Sciences, Krainer and colleagues report their discovery of three factors that contribute to high levels of PK-M2 in cancer cells, in part by suppressing production of PK-M1.

"These findings suggest a new way in which cancer's altered glucose metabolism might be targeted for therapeutic benefit," explains Krainer. "Drugs that inhibit these factors and reverse the Warburg effect might work as anti-cancer agents." The study was performed in collaboration with Professor Lewis Cantley, Ph.D., and his colleagues at Harvard Medical School and The Broad Institute, in Cambridge, Mass.

Cancer cells consume glucose at a much higher rate than normal cells, but use very little glucose to produce energy, spending the rest instead on cell-building material. They also produce huge amounts of a byproduct called lactate. PK-M2, which facilitates this alternate metabolic lifestyle in cancer cells, was recently shown by the Cantley laboratory to be critical for tumor formation and growth.

This isoform and its non-cancerous counterpart PK-M1, which is found only in normal cells, both arise from the same gene, PK-M, via alternative splicing, a process that allows a single gene to produce multiple proteins. The initial RNA copy of a gene's DNA includes unnecessary pieces called introns that are first spliced out. The remaining bits, called exons, can be stitched back together in different ways by the cell's splicing machinery to form different RNAs that can then give rise to different proteins.

In the case of the PK-M gene, its RNA undergoes alternative splicing in a mutually exclusive fashion, giving rise to either the M1 or the M2 isoform. Krainer, an expert on alternative splicing, has been focused on understanding how the benign M1 isoform is switched off and the dangerous M2 isoform switched on in cancer cells. His team began by tracking down splicing factors and mechanisms that cause cancer cells to exclusively produce the M2 isoform.

By examining the levels of various splicing factors in numerous types of cancer cells, the scientists have narrowed the list of suspects to three proteins so far. All three are present at high levels in cancer cells, and repress the splicing of the harmless M1 isoform. This, by default, causes cells to produce only the M2 isoform.

The scientists could largely reverse this situation restoring M1 production while decreasing M2 levels and lactate production by forcing a reduction in the levels of the three splicing repressors. Whether this switch back to normal metabolism also impedes cancer cells' rapid growth remains to be tested.

"The cells didn't completely stop producing M2 when the three repressor proteins were blocked, which suggests that there might be other splicing factors that influence the switch between the two isoforms," explains Krainer. The team is now looking for these other potential splicing regulators.

"The field of cancer metabolism has reemerged, but several fundamental questions still remain about how the Warburg effect works," says Krainer. "We hope that our research on how alternative splicing regulates cellular metabolism will help fill in this puzzle and uncover new molecular drug targets."


'/>"/>

Contact: Peter Tarr
tarr@cshl.edu
516-367-8455
Cold Spring Harbor Laboratory
Source:Eurekalert

Related medicine news :

1. Study shows genital herpes virus reactivates widely throughout genital tract
2. Study finds face masks and hand hygiene can help limit influenzas spread
3. New study shows TGen spin-off boosts Scottsdale economy
4. Herpes medication does not reduce risk of HIV transmission, UW-led international study finds
5. Mouse Study May Advance Multiple Sclerosis Research
6. Employer Satisfaction With Health Insurers Is Declining, Finds PricewaterhouseCoopers Study
7. Employer Satisfaction with Health Insurers is Declining, Finds PricewaterhouseCoopers Study
8. Study Questions Need for Emergency Appendectomies
9. Treatment for chronic hepatitis C: A phase II study
10. Zambian study finds longer breastfeeding best for HIV-infected mothers
11. Refinement of glaucoma testing, treatment expected from US, United Kingdom study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to Best ... individuals in the United States and Canada wear eyeglasses. Once considered to be a ... and make a fashion statement. Even celebrities use glasses as a way of creating ...
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
(Date:6/25/2016)... ... 25, 2016 , ... Austin residents seeking Mohs surgery services, can now turn ... to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization ... selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. ... his M.D from the David Geffen School of Medicine at UCLA. He trained in ... to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published ... unfamiliar with. The article goes on to state that individuals are now more comfortable ... less common operations such as calf and cheek reduction. The Los Angeles area medical ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
Breaking Medicine Technology: